Internal: Archive

Adecco appoints new finance chief

This content was published on Apr 23, 2004 Fredholm, currently at Deutsche Post World Net, will join Adecco on June 1. Adecco, which is eager to try to restore credibility after twice delaying publication of its 2003 results, said on Friday that it was “delighted” at the appointment. “We believe his strong background in accounting, finance and controls acquired in several large global…

Italian bargain hunters flock to Switzerland

This content was published on Apr 23, 2004 The most sought-after items are Italian-made designer goods, but shoppers are also filling their bags with food and Italian wine. “It’s like bringing water to the sea,” says Lugano shopkeeper, Lino Gabbani, explaining how he is selling more and more Italian wine to Italian customers. Gabbani owns a handful of colourful shops in Lugano’s pedestrian…

Novartis opens merger talks with Aventis

This content was published on Apr 22, 2004 Novartis said on Thursday that it would begin merger talks with Aventis but added it was not sure it could cement a deal. “We know how compelling the project is,” said Raymund Breu, chief financial officer at Novartis. Although the Basel-based firm has downplayed its chances of clinching the deal, a partnership with Aventis would…

Dairy producers battle for market share

This content was published on Apr 22, 2004 But competition in a limited domestic market remains tough for both big producers and small dairy firms. Last year Lucerne-based Emmi more than doubled its net profit to SFr47.2 million ($35.9 million) as it snapped up units and branched into new product areas. Sales in 2003 rose by 35 per cent to nearly SFr1.9 billion,…

Plans unveiled for giant Zurich science campus

This content was published on Apr 22, 2004 On Wednesday the institute revealed that the project, scheduled for completion by 2010, is expected to cost SFr400 million ($305 million). According to the institute, SFr250 million will be spent on the construction of new buildings, while SFr150 million is to be invested in scientific equipment. “We want to remain one of the best universities…

Franz admits piloting Swiss will be challenging

This content was published on Apr 20, 2004 Christoph Franz could only laugh when swissinfo asked him how it felt to take up possibly one of the most unenviable jobs in Switzerland. “I think it is one of the most challenging positions especially in the situation we have at Swiss at the moment,” the German commented. “But every challenge is also a possibility…

Franz faces uphill struggle to turn Swiss around

This content was published on Apr 20, 2004 But some aviation analysts have greeted his appointment with scepticism and warned that the 43-year-old German will struggle to succeed where his predecessor failed. “The task will not be simple for Franz,” warned Patrik Schwendimann, an analyst at Zurich Cantonal Bank. “In the long run he has to prove himself, and he is dependent on…

Tourism tries the hard sell

This content was published on Apr 20, 2004 But there are tensions between the national tourist office and its members about how to promote Switzerland abroad. Some 1,150 representatives from the industry – from tourism managers to hoteliers – have been taking part in the conference which opened on Monday in Bern. The main theme of this year’s event is how to sell…

Swiss names new CEO

This content was published on Apr 19, 2004 Franz, who takes up his position at Swiss in July, previously worked for the German airline, Lufthansa, and Germany’s national railway, Deutsche Bahn. Franz was chosen from a final shortlist of six. The selection process was led by Swiss chairman and acting CEO, Pieter Bouw. “Swiss chose Christoph Franz because of his track record in…

Uni Basel spin-off joins antibody-based drug race

This content was published on Apr 19, 2004 With research grants and seed funding the firm is on its way to staking a claim in an emerging new field within the biotech sector. The biotech industry is hoping that antibodies, which traditionally protect mammals against disease, can be developed and produced on an industrial scale for treating cancer and other illnesses, even allergies,…

Internal: Archive

Popular Stories

Most Discussed

Internal: Archive

More

Adecco appoints new finance chief

More

Italian bargain hunters flock to Switzerland

More

Novartis opens merger talks with Aventis

More

Dairy producers battle for market share

More

Plans unveiled for giant Zurich science campus

More

Franz admits piloting Swiss will be challenging

More

Franz faces uphill struggle to turn Swiss around

More

Tourism tries the hard sell

More

Swiss names new CEO

More

Uni Basel spin-off joins antibody-based drug race

Popular Stories

Most Discussed